Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats

Takeshi Nishida, Maho Tsubota, Yudai Kawaishi, Hiroki Yamanishi, Natsuki Kamitani, Fumiko Sekiguchi, Hiroyasu Ishikura, Keyue Liu, Masahiro Nishibori, Atsufumi Kawabata

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Given that high mobility group box 1 (HMGB1), a nuclear protein, once released to the extracellular space, promotes nociception, we asked if inactivation of HMGB1 prevents or reverses chemotherapy-induced painful neuropathy in rats and also examined possible involvement of Toll-like receptor 4 (TLR4) and the receptor for advanced glycation endproduct (RAGE), known as targets for HMGB1. Painful neuropathy was produced by repeated i.p. administration of paclitaxel or vincristine in rats. Nociceptive threshold was determined by the paw pressure method and/or von Frey test in the hindpaw. Tissue protein levels were determined by immunoblotting. Repeated i.p. administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats. A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy. A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the hyperalgesia caused by i.pl. HMGB1 and also the chemotherapy-induced painful neuropathy. Paclitaxel or vincristine treatment significantly decreased protein levels of HMGB1 in the dorsal root ganglia, but not sciatic nerves. HMGB1 thus participates in both development and maintenance of chemotherapy-induced painful neuropathy, in part through RAGE and TLR4. HMGB1 inactivation is considered useful to prevent and treat the chemotherapy-induced painful neuropathy.

Original languageEnglish
Pages (from-to)48-58
Number of pages11
JournalToxicology
Volume365
DOIs
Publication statusPublished - Jul 15 2016

Fingerprint

Maintenance Chemotherapy
Chemotherapy
Peripheral Nervous System Diseases
Rats
Toll-Like Receptor 4
Hyperalgesia
Vincristine
Paclitaxel
Thrombomodulin
Drug Therapy
HMGB1 Protein
Nociception
Low Molecular Weight Heparin
Extracellular Space
Spinal Ganglia
Sciatic Nerve
Nuclear Proteins
Neutralizing Antibodies
Immunoblotting
Proteins

Keywords

  • Chemotherapy-induced painful neuropathy
  • High mobility group box 1
  • Neuropathic pain
  • Thrombomodulin

ASJC Scopus subject areas

  • Medicine(all)
  • Toxicology

Cite this

Nishida, T., Tsubota, M., Kawaishi, Y., Yamanishi, H., Kamitani, N., Sekiguchi, F., ... Kawabata, A. (2016). Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology, 365, 48-58. https://doi.org/10.1016/j.tox.2016.07.016

Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. / Nishida, Takeshi; Tsubota, Maho; Kawaishi, Yudai; Yamanishi, Hiroki; Kamitani, Natsuki; Sekiguchi, Fumiko; Ishikura, Hiroyasu; Liu, Keyue; Nishibori, Masahiro; Kawabata, Atsufumi.

In: Toxicology, Vol. 365, 15.07.2016, p. 48-58.

Research output: Contribution to journalArticle

Nishida, T, Tsubota, M, Kawaishi, Y, Yamanishi, H, Kamitani, N, Sekiguchi, F, Ishikura, H, Liu, K, Nishibori, M & Kawabata, A 2016, 'Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats', Toxicology, vol. 365, pp. 48-58. https://doi.org/10.1016/j.tox.2016.07.016
Nishida, Takeshi ; Tsubota, Maho ; Kawaishi, Yudai ; Yamanishi, Hiroki ; Kamitani, Natsuki ; Sekiguchi, Fumiko ; Ishikura, Hiroyasu ; Liu, Keyue ; Nishibori, Masahiro ; Kawabata, Atsufumi. / Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. In: Toxicology. 2016 ; Vol. 365. pp. 48-58.
@article{342f691b3804433b9500af399f659d04,
title = "Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats",
abstract = "Given that high mobility group box 1 (HMGB1), a nuclear protein, once released to the extracellular space, promotes nociception, we asked if inactivation of HMGB1 prevents or reverses chemotherapy-induced painful neuropathy in rats and also examined possible involvement of Toll-like receptor 4 (TLR4) and the receptor for advanced glycation endproduct (RAGE), known as targets for HMGB1. Painful neuropathy was produced by repeated i.p. administration of paclitaxel or vincristine in rats. Nociceptive threshold was determined by the paw pressure method and/or von Frey test in the hindpaw. Tissue protein levels were determined by immunoblotting. Repeated i.p. administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats. A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy. A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the hyperalgesia caused by i.pl. HMGB1 and also the chemotherapy-induced painful neuropathy. Paclitaxel or vincristine treatment significantly decreased protein levels of HMGB1 in the dorsal root ganglia, but not sciatic nerves. HMGB1 thus participates in both development and maintenance of chemotherapy-induced painful neuropathy, in part through RAGE and TLR4. HMGB1 inactivation is considered useful to prevent and treat the chemotherapy-induced painful neuropathy.",
keywords = "Chemotherapy-induced painful neuropathy, High mobility group box 1, Neuropathic pain, Thrombomodulin",
author = "Takeshi Nishida and Maho Tsubota and Yudai Kawaishi and Hiroki Yamanishi and Natsuki Kamitani and Fumiko Sekiguchi and Hiroyasu Ishikura and Keyue Liu and Masahiro Nishibori and Atsufumi Kawabata",
year = "2016",
month = "7",
day = "15",
doi = "10.1016/j.tox.2016.07.016",
language = "English",
volume = "365",
pages = "48--58",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats

AU - Nishida, Takeshi

AU - Tsubota, Maho

AU - Kawaishi, Yudai

AU - Yamanishi, Hiroki

AU - Kamitani, Natsuki

AU - Sekiguchi, Fumiko

AU - Ishikura, Hiroyasu

AU - Liu, Keyue

AU - Nishibori, Masahiro

AU - Kawabata, Atsufumi

PY - 2016/7/15

Y1 - 2016/7/15

N2 - Given that high mobility group box 1 (HMGB1), a nuclear protein, once released to the extracellular space, promotes nociception, we asked if inactivation of HMGB1 prevents or reverses chemotherapy-induced painful neuropathy in rats and also examined possible involvement of Toll-like receptor 4 (TLR4) and the receptor for advanced glycation endproduct (RAGE), known as targets for HMGB1. Painful neuropathy was produced by repeated i.p. administration of paclitaxel or vincristine in rats. Nociceptive threshold was determined by the paw pressure method and/or von Frey test in the hindpaw. Tissue protein levels were determined by immunoblotting. Repeated i.p. administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats. A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy. A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the hyperalgesia caused by i.pl. HMGB1 and also the chemotherapy-induced painful neuropathy. Paclitaxel or vincristine treatment significantly decreased protein levels of HMGB1 in the dorsal root ganglia, but not sciatic nerves. HMGB1 thus participates in both development and maintenance of chemotherapy-induced painful neuropathy, in part through RAGE and TLR4. HMGB1 inactivation is considered useful to prevent and treat the chemotherapy-induced painful neuropathy.

AB - Given that high mobility group box 1 (HMGB1), a nuclear protein, once released to the extracellular space, promotes nociception, we asked if inactivation of HMGB1 prevents or reverses chemotherapy-induced painful neuropathy in rats and also examined possible involvement of Toll-like receptor 4 (TLR4) and the receptor for advanced glycation endproduct (RAGE), known as targets for HMGB1. Painful neuropathy was produced by repeated i.p. administration of paclitaxel or vincristine in rats. Nociceptive threshold was determined by the paw pressure method and/or von Frey test in the hindpaw. Tissue protein levels were determined by immunoblotting. Repeated i.p. administration of the anti-HMGB1-neutralizing antibody or recombinant human soluble thrombomodulin (rhsTM), known to inactivate HMGB1, prevented the development of hyperalgesia and/or allodynia induced by paclitaxel or vincristine in rats. A single i.p. or intraplantar (i.pl.) administration of the antibody or rhsTM reversed the chemotherapy-induced neuropathy. A single i.pl. administration of a TLR4 antagonist or low molecular weight heparin, known to inhibit RAGE, attenuated the hyperalgesia caused by i.pl. HMGB1 and also the chemotherapy-induced painful neuropathy. Paclitaxel or vincristine treatment significantly decreased protein levels of HMGB1 in the dorsal root ganglia, but not sciatic nerves. HMGB1 thus participates in both development and maintenance of chemotherapy-induced painful neuropathy, in part through RAGE and TLR4. HMGB1 inactivation is considered useful to prevent and treat the chemotherapy-induced painful neuropathy.

KW - Chemotherapy-induced painful neuropathy

KW - High mobility group box 1

KW - Neuropathic pain

KW - Thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=84982817550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982817550&partnerID=8YFLogxK

U2 - 10.1016/j.tox.2016.07.016

DO - 10.1016/j.tox.2016.07.016

M3 - Article

C2 - 27474498

AN - SCOPUS:84982817550

VL - 365

SP - 48

EP - 58

JO - Toxicology

JF - Toxicology

SN - 0300-483X

ER -